Nathan Jetter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nathan Jetter has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar L. Krunic
Department of Dermatology, School of Medicine, Northwestern University Feinberg, Chicago, USA
2 shared publications - Felipe Bochnia Cerci
Clínica Cepelle Curitiba Brazil
2 shared publications - Karan Pandher
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, USA
2 shared publications - Alan Schwartz
University of Illinois at Chicago
1 shared publication - Jeffrey R. Rajkumar
University of Illinois College of Medicine at Chicago Chicago IL USA
1 shared publication - Katy Samuels1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (4) , 520-523
Desenvolvimento de pênfigo vegetante após cirurgia micrográfica de Mohs e crioterapia
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (4) , 520-523
Open AccessDesenvolvimento de pênfigo vegetante após cirurgia micrográfica de Mohs e crioterapia
- Open Access
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (4) , 520-523
Pemphigus vegetans developing after Mohs micrographic surgery and cryotherapy
- 1 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (4) , 520-523
Open AccessPemphigus vegetans developing after Mohs micrographic surgery and cryotherapy
- 12 December 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (3) , 623-628
Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A two‐year case series of patient‐reported outcomes
Background: Eczema treatments that target Staphylococcus aureus include topical mixtures of antimicrobial agent and corticosteroid diluted in a moisturizer base, previously described in the literature as compounded antibacterial, steroid, and moisturizer (CASM). There have been no placebo‐controlled blinded studies of CASM. Thus, patient‐reported outcome data may prove valuable.Objective: To determine the patient‐reported clinical course of eczema treatment with CASM.Methods: Longitudinal case series between May 2016 and August 2018 of CASM patients/parents. Patients completed surveys including the POEM measure at start of treatment, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months thereafter. Response curves were fitted to severity measures over time and compared by patient age group; survival analysis was used to estimate time‐to‐clear status as a function of patient age and initial severity.Results: A total of 2153 reports were received from 728 unique respondents with a median patient age of 7 and range of 0‐85. Response curves showed significant improvement over time leading to plateaus between 30 and 60 days of treatment. Overall mean improvement between start and day 90 for POEM was 14.3 (from 20.0 [95% CI 11.4‐28.8] to 5.7 [95% CI −3.2 to 14.8]). Improvement was seen in each age group.Conclusions: Patient‐reported outcomes suggest efficacy of CASM. There were large reductions in POEM scores, mostly in the first 30 days of treatment for all age groups.
- 12 December 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (3) , 623-628
Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A two‐year case series of patient‐reported outcomes
Background: Eczema treatments that target Staphylococcus aureus include topical mixtures of antimicrobial agent and corticosteroid diluted in a moisturizer base, previously described in the literature as compounded antibacterial, steroid, and moisturizer (CASM). There have been no placebo‐controlled blinded studies of CASM. Thus, patient‐reported outcome data may prove valuable.Objective: To determine the patient‐reported clinical course of eczema treatment with CASM.Methods: Longitudinal case series between May 2016 and August 2018 of CASM patients/parents. Patients completed surveys including the POEM measure at start of treatment, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months, and 12 months thereafter. Response curves were fitted to severity measures over time and compared by patient age group; survival analysis was used to estimate time‐to‐clear status as a function of patient age and initial severity.Results: A total of 2153 reports were received from 728 unique respondents with a median patient age of 7 and range of 0‐85. Response curves showed significant improvement over time leading to plateaus between 30 and 60 days of treatment. Overall mean improvement between start and day 90 for POEM was 14.3 (from 20.0 [95% CI 11.4‐28.8] to 5.7 [95% CI −3.2 to 14.8]). Improvement was seen in each age group.Conclusions: Patient‐reported outcomes suggest efficacy of CASM. There were large reductions in POEM scores, mostly in the first 30 days of treatment for all age groups.